Embrace higher titers and robust yield. Our optimized, end-to-end VirusExpress® lentivirus platform delivering maximized production and quality outcomes to enable the success for your cell or gene therapy. Benefit from accelerated development timelines, de-risked manufacturing, and achieve the performance and product quality critical for clinical trials, all while delivering a lower cost per therapeutic dose.
In this webinar, you will discover how our comprehensive lentivirus platform enables clinical and commercial success by:
- Accelerating timelines
- Achieving higher titers and quality per batch
- Conserving your time and resources
- Delivering lower cost/ therapeutic dose
Speaker
Katie Schewe
Merck
Product Manager, Upstream Bioprocessing
Katie Schewe is a product manager in the upstream bioprocessing group. She has been with Merck for more than 5 years in various roles from product management to quality assurance of API manufacturing. Prior, she worked at Eli Lilly and Co. in various analytical R&D roles for both large and small molecules as well as in field sales.
Katie has a background in chemistry with her master’s degree in Chemistry from IUPUI—Indianapolis. She has experience ranging from manufacturing to field sales to help better understand the needs of our customers to deliver solutions.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
Duration:39min
Language:English
Session 1:presented June 6, 2024
To continue reading please sign in or create an account.
Don't Have An Account?